Literature DB >> 7840779

Uptake and cytotoxicity of 9-methoxy-N2-methylellipticinium acetate in human brain and non-brain tumor cell lines.

S Kenney1, D T Vistica, H Linden, M R Boyd.   

Abstract

9-Methoxy-N2-methylellipticinium acetate (MMEA) was preferentially cytotoxic to human brain tumor cell lines in the in vitro primary screen of the U.S. National Cancer Institute. In the present study, the average intracellular accumulation of radioactivity derived from [14C]MMEA concentrations that were selectively cytotoxic to sensitive brain tumor cell lines was nearly 4-fold greater than in human tumor cell lines derived from the lung, kidney, ovary and colon. The extent of peak cellular accumulation of [14C]MMEA-derived radioactivity, achieved after 10-15 hr of drug exposure, was correlated positively with relative MMEA cytotoxicity in brain tumor cell lines (r2 = 0.963). A similar correlation (r2 = 0.967) was observed in selected non-brain tumor cell lines but required substantially higher (18-fold) concentrations of MMEA. [14C]MMEA radioactivity accumulation by a selected glioblastoma cell line occurred via an energy-requiring system that was predominantly sodium and pH independent.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7840779     DOI: 10.1016/0006-2952(94)00471-w

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  2 in total

1.  Old drug, new target: ellipticines selectively inhibit RNA polymerase I transcription.

Authors:  William J Andrews; Tatiana Panova; Christophe Normand; Olivier Gadal; Irina G Tikhonova; Konstantin I Panov
Journal:  J Biol Chem       Date:  2013-01-04       Impact factor: 5.157

2.  The collective nuclear migration of p53 and phosphorylated S473 of Akt during ellipticine-mediated apoptosis in human lung epithelial cancer cells.

Authors:  Jing-Ping Wang; Ya-Chu Yu; Shih-Ping Chen; Huan-Chang Liang; Chia-Wei Lin; Kang Fang
Journal:  Mol Cell Biochem       Date:  2015-05-27       Impact factor: 3.396

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.